Checkpoint inhibitors and CAR-T cell therapy have become household words in pharma circles, but tissue-derived gamma delta T-cells are not widely talked about…yet. This relatively under-explored aspect of immune biology may be able to provide useful additional tools in the growing immunotherapy armamentarium, as a deal signed last week by Takeda Pharmaceutical Co. Ltd. highlights.
The Japanese firm has bought a stake in GammaDelta Therapeutics Ltd, a start-up spun out of UK academia only last...







